<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9818">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00716963</url>
  </required_header>
  <id_info>
    <org_study_id>AZ2008lr</org_study_id>
    <nct_id>NCT00716963</nct_id>
  </id_info>
  <brief_title>Does Fluticasone Propionate Reduce the Late Allergic Reaction When the Drug is Given Post-allergen?</brief_title>
  <official_title>Does a Lipophilic Steroid Inhaled After an Early Allergic Reaction Affect the Late Reaction?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose a 3-treatment, placebo-controlled, double-dummy, double-blinded,
      randomized, crossover study in which single doses of placebo, will be compared to
      Fluticasone propionate (Flovent Diskus) 250 mcg and budesonide 400 mcg administered after
      allergen challenge, at cessation of the early allergic reaction (at 20% fall in FEV1 from
      post-allergen peak)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this pilot study is to evaluate whether fluticasone propionate affects the late
      allergic reaction after a single dose post-allergen challenge administered following
      cessation of the early allergic reaction.

      Six subjects with mild asthma will be asked to volunteer for the study.The diagnosis of
      asthma will be and includes the presence of variable airflow limitation and AHR (PC20
      methacholine &lt; 16 mg/mL). Subjects will be asked to participate if they demonstrate an
      allergen-induced early and late asthmatic response of at least 20% and 15% reduction in
      FEV1, respectively.

      The study will consist of 4 periods, composed of a screening allergen period with 3
      subsequent allergen challenge/treatment periods. Each period will be separated with a
      washout of at least 2 weeks. Subjects who demonstrate a dual asthmatic response in the
      screening period will be selected for randomization to treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>The Magnitude of the Early Asthmatic Response, Expressed as a Percentage Fall in FEV1.</measure>
    <time_frame>Before inhalation 3 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>The Magnitude of the Late Asthmatic Response, Expressed as a Percentage Fall in FEV1.</measure>
    <time_frame>7 hours after challenge</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Magnitude of Allergen-induced Airway Hyperresponsiveness (Methacholine PC20) and Inflammation (Sputum Eosinophils).</measure>
    <time_frame>Before inhalation both evaluations (0 hours)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Magnitude of Allergen-induced Airway Hyperresponsiveness (Methacholine PC20) and Inflammation (Sputum Eosinophils)</measure>
    <time_frame>sputum @ 7 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Magnitude of Allergen-induced Airway Hyperresponsiveness (Methacholine PC20) and Inflammation (Sputum Eosinophils)</measure>
    <time_frame>24 hours methacholine and sputum</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Mild Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluticasone propionate (Flovent Diskus) 250 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>budesonide 400mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone propionate (Flovent Diskus) 250 mcg</intervention_name>
    <description>Flovent Diskus 250 mcg</description>
    <arm_group_label>1</arm_group_label>
    <other_name>fluticasone propionate Flovent Diskus250 mcg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide 400 mcg</intervention_name>
    <description>budesonide 400 mcg</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Pulmicort Turbuhaler 200 mcg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  mild asthma

          -  nonsmokers

          -  allergen-induced early and late asthmatic response

        Exclusion Criteria:

          -  no medication other than infrequent ( &lt; twice weekly) inhaled beta2-agonists

          -  not be exposed to sensitizing allergens

          -  asthma exacerbation or respiratory tract infection in the past4 weeks
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul O'Byrne, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gail Gauvreau, PhD</last_name>
    <role>Study Director</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Bousquet J, Clark TJ, Hurd S, Khaltaev N, Lenfant C, O'byrne P, Sheffer A. GINA guidelines on asthma and beyond. Allergy. 2007 Feb;62(2):102-12. Review.</citation>
    <PMID>17298416</PMID>
  </reference>
  <reference>
    <citation>Gauvreau GM, Doctor J, Watson RM, Jordana M, O'Byrne PM. Effects of inhaled budesonide on allergen-induced airway responses and airway inflammation. Am J Respir Crit Care Med. 1996 Nov;154(5):1267-71.</citation>
    <PMID>8912734</PMID>
  </reference>
  <reference>
    <citation>Paggiaro PL, Dente FL, Morelli MC, Bancalari L, Di Franco A, Giannini D, Vagaggini B, Bacci E, Fabbri LM, Giuntini C. Postallergen inhaled budesonide reduces late asthmatic response and inhibits the associated increase of airway responsiveness to methacholine in asthmatics. Am J Respir Crit Care Med. 1994 Jun;149(6):1447-51.</citation>
    <PMID>8004297</PMID>
  </reference>
  <reference>
    <citation>Duong M, Gauvreau G, Watson R, Obminski G, Strinich T, Evans M, Howie K, Killian K, O'Byrne PM. The effects of inhaled budesonide and formoterol in combination and alone when given directly after allergen challenge. J Allergy Clin Immunol. 2007 Feb;119(2):322-7. Epub 2006 Dec 4.</citation>
    <PMID>17141859</PMID>
  </reference>
  <reference>
    <citation>Cockcroft DW, McParland CP, O'Byrne PM, Manning P, Friend JL, Rutherford BC, Swystun VA. Beclomethasone given after the early asthmatic response inhibits the late response and the increased methacholine responsiveness and cromolyn does not. J Allergy Clin Immunol. 1993 Jun;91(6):1163-8.</citation>
    <PMID>8509579</PMID>
  </reference>
  <reference>
    <citation>Boulet LP, Gauvreau G, Boulay ME, O'Byrne P, Cockcroft DW; Clinical Investigative Collaboration, Canadian Network of Centers of Excellence AllerGen. The allergen bronchoprovocation model: an important tool for the investigation of new asthma anti-inflammatory therapies. Allergy. 2007 Oct;62(10):1101-10. Review.</citation>
    <PMID>17845579</PMID>
  </reference>
  <reference>
    <citation>Gauvreau GM, Boulet LP, Hessel EM, Watson RM, Milot J, Coffman RL, et al. A phase 2, randomized, observer-blind, placebo-controlled study of the efficacy, safety and tolerability of inhaled 1018 ISS immunostimulatory oligonucleotide in subjects with mild to moderate asthma. Am.J.Respir.Crit Care Med. 171, A81. 2005. Ref Type: Abstract</citation>
  </reference>
  <reference>
    <citation>Cockcroft DW, Murdock KY, Kirby J, Hargreave F. Prediction of airway responsiveness to allergen from skin sensitivity to allergen and airway responsiveness to histamine. Am Rev Respir Dis. 1987 Jan;135(1):264-7.</citation>
    <PMID>3800152</PMID>
  </reference>
  <reference>
    <citation>Cockcroft DW, Davis BE, Boulet LP, Deschesnes F, Gauvreau GM, O'Byrne PM, Watson RM. The links between allergen skin test sensitivity, airway responsiveness and airway response to allergen. Allergy. 2005 Jan;60(1):56-9.</citation>
    <PMID>15575931</PMID>
  </reference>
  <reference>
    <citation>Pizzichini E, Pizzichini MM, Efthimiadis A, Evans S, Morris MM, Squillace D, Gleich GJ, Dolovich J, Hargreave FE. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med. 1996 Aug;154(2 Pt 1):308-17.</citation>
    <PMID>8756799</PMID>
  </reference>
  <reference>
    <citation>O'Byrne PM, Dolovich J, Hargreave FE. Late asthmatic responses. Am Rev Respir Dis. 1987 Sep;136(3):740-51. Review.</citation>
    <PMID>3115156</PMID>
  </reference>
  <reference>
    <citation>Inman MD, Watson R, Cockcroft DW, Wong BJ, Hargreave FE, O'Byrne PM. Reproducibility of allergen-induced early and late asthmatic responses. J Allergy Clin Immunol. 1995 Jun;95(6):1191-5.</citation>
    <PMID>7797787</PMID>
  </reference>
  <reference>
    <citation>Gauvreau GM, Watson RM, Rerecich TJ, Baswick E, Inman MD, O'Byrne PM. Repeatability of allergen-induced airway inflammation. J Allergy Clin Immunol. 1999 Jul;104(1):66-71.</citation>
    <PMID>10400841</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 30, 2015</lastchanged_date>
  <firstreceived_date>July 14, 2008</firstreceived_date>
  <firstreceived_results_date>April 14, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McMaster University</investigator_affiliation>
    <investigator_full_name>Gail Gauvreau</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>late allergic response</keyword>
  <keyword>fluticasone propionate</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Fluticasone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fluticasone/Budesonide/Placebo</title>
          <description>Subjects receive Fluticasone after early allergic response induced by allergen challenge. At least 2 week wash out period. Subjects receive Budesonide after early allergic response induced by allergen challenge. At least 2 week wash out period. Subjects receive placebo after early allergic response induced by allergen challenge.</description>
        </group>
        <group group_id="P2">
          <title>Fluticasone/Placebo/Budesonide</title>
          <description>Subjects receive Fluticasone after early allergic response induced by allergen challenge. At least 2 week wash out period. Subjects receive placebo after early allergic response induced by allergen challenge. At least 2 week wash out period. Subjects receive Budesonide after early allergic response induced by allergen challenge.</description>
        </group>
        <group group_id="P3">
          <title>Budesonide/Fluticasone/Placebo</title>
          <description>Subjects receive Budesonide after early allergic response induced by allergen challenge. At least 2 week wash out period. Subjects receive Fluticasone after early allergic response induced by allergen challenge. At least 2 week wash out period. Subjects receive placebo after early allergic response induced by allergen challenge.</description>
        </group>
        <group group_id="P4">
          <title>Budesonide/Placebo/Fluticasone</title>
          <description>Subjects receive Budesonide after early allergic response induced by allergen challenge. At least 2 week wash out period. Subjects receive placebo after early allergic response induced by allergen challenge. At least 2 week wash out period. Subjects receive Fluticasone after early allergic response induced by allergen challenge.</description>
        </group>
        <group group_id="P5">
          <title>Placebo/Fluticasone/Budesonide</title>
          <description>Subjects receive placebo after early allergic response induced by allergen challenge. At least 2 week wash out period. Subjects receive Fluticasone after early allergic response induced by allergen challenge. At least 2 week wash out period. Subjects receive Budesonide after early allergic response induced by allergen challenge.</description>
        </group>
        <group group_id="P6">
          <title>Placebo/Budesonide/Fluticasone</title>
          <description>Subjects receive placebo after early allergic response induced by allergen challenge. At least 2 week wash out period. Subjects receive Budesonide after early allergic response induced by allergen challenge. At least 2 week wash out period. Subjects receive Fluticasone after early allergic response induced by allergen challenge.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Screening/Baseline Participants</title>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Magnitude of the Early Asthmatic Response, Expressed as a Percentage Fall in FEV1.</title>
        <time_frame>Before inhalation 3 hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>Instead of re-listing participant flow, data was taken from each subject arm and re-listed here as the 3 arms each subject underwent.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Propionate (Flovent Diskus) 250 mcg</title>
          </group>
          <group group_id="O2">
            <title>Budesonide 400mcg</title>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Magnitude of the Early Asthmatic Response, Expressed as a Percentage Fall in FEV1.</title>
            <units>percentage fall FEV1</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-30.5" spread="9.3"/>
                  <measurement group_id="O2" value="-39.0" spread="12.3"/>
                  <measurement group_id="O3" value="-31.9" spread="10.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Magnitude of the Late Asthmatic Response, Expressed as a Percentage Fall in FEV1.</title>
        <time_frame>7 hours after challenge</time_frame>
        <safety_issue>No</safety_issue>
        <population>Instead of re-listing participant flow, data was taken from each subject arm and re-listed here as the 3 arms each subject underwent.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Propionate (Flovent Diskus) 250 mcg</title>
          </group>
          <group group_id="O2">
            <title>Budesonide 400mcg</title>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Magnitude of the Late Asthmatic Response, Expressed as a Percentage Fall in FEV1.</title>
            <units>percentage fall FEV1</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-11.6" spread="14.2"/>
                  <measurement group_id="O2" value="-14.7" spread="6.6"/>
                  <measurement group_id="O3" value="-24" spread="7.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Magnitude of Allergen-induced Airway Hyperresponsiveness (Methacholine PC20) and Inflammation (Sputum Eosinophils).</title>
        <time_frame>Before inhalation both evaluations (0 hours)</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Magnitude of Allergen-induced Airway Hyperresponsiveness (Methacholine PC20) and Inflammation (Sputum Eosinophils)</title>
        <time_frame>sputum @ 7 hours</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Magnitude of Allergen-induced Airway Hyperresponsiveness (Methacholine PC20) and Inflammation (Sputum Eosinophils)</title>
        <time_frame>24 hours methacholine and sputum</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Fluticasone Propionate (Flovent Diskus) 250 mcg</title>
        </group>
        <group group_id="E2">
          <title>Budesonide 400mcg</title>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Gail Gauvreau</name_or_title>
      <organization>McMaster University</organization>
      <phone>905-525-9140 ext 22791</phone>
      <email>gauvreau@mcmaster.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
